Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Vitamin D2 to Treat Chronic Kidney Disease Mineral and Bone Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with age between 18-75 years.~* Patients with chronic kidney disease stage 3 to 5, and concurrent chronic kidney disease mineral and bone disorder.~Exclusion Criteria:~* Renal artery stenosis, inherent renal malformation, solitary kidney, or malignancy in urinary system.~* New fracture in last 3 months.~* Active system immunity diseases.~* History of liver failure~* History of intestinal malabsorption or chronic diarrhea~* Treatment with phenobarbital, phenytoin, rifampicin, sucralfate, steroids, digoxin, or other medications that could affect vitamin D metabolism~* Primary hyperparathyroidism~* Treatment with cinacalcet or other calcimimetic within the past 6 months~* Anticipated dialysis within 6 months after randomization~* Have an unstable medical condition, defined as having been hospitalized within 30 days before screening, the expectation of recurrent hospital admissions or life expectancy of less than 6 months in the judgment of the investigator~* Subject is currently enrolled in, or fewer than 30 days have passed since subject has completed another investigational device or drug study(s); or subject is receiving another investigational agent(s).~* Current treatment with vitamin D 50,000 IU~* Using glucocorticoid or immunosuppressive agents.~* Acute renal dysfunction.~* The expected live time is less than 2 years.~* Pregnant or lactating woman.~* Suffered from acute myocardial infraction, acute congestive heart failure, or stroke in last 6 months.~* Patients whose concurrent illnesses, disability, or geographical residence would hamper attendance at required study visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Vitamin D2 Treatment (Type: EXPERIMENTAL): Patients will be treated by vitamin D2. Oral Vit D2 1.25mg(50,000 unit) once weekly as a start and maintain 1.25mg(50,000 unit) once monthly according to the blood 25(OH)vitamin D level.
- 1,25(OH)2 Vitamin D3 (Type: ACTIVE_COMPARATOR): Patients will be treated by 1,25(OH)2 Vitamin D3. Oral 1,25(OH)2 Vitamin D3(Rocaltrol) by 0.25 microgram once daily at start and regulate the dose according to the changes of blood levels of 25(OH)Vit D, calcium, phosphorus, and intact parathyroid hormone.

Based on this trial design, predict the completion outcome and termination type (if applicable).